BP Lipid 312 is a proprietary ionizable lipid developed by BroadPharm, designed for comparison with lipid LP01 and other related lipids. It features a key structural modification—the substitution of a polyunsaturated tail with a monounsaturated equivalent—which may influence lipid nanoparticle performance. BP Lipid 312 has been utilized in the formulation of lipid nanoparticles (LNPs) for the delivery of CRISPR-Cas9 RNA, as demonstrated in product citations (see below). This product is provided at reagent grade, intended for research use only. For inquiries regarding GMP-grade material, please contact us directly.
Usually ships within 24 hours.